Impact of Non-Alcoholic Simple Fatty Liver Disease on Antituberculosis Drug-Induced Liver Injury

References

• LomtadzeN, KupreishviliL, SalakaiaA, et al. Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis. PLoS One. 2013;8(12):e83892. doi:10.1371/journal.pone.008389224367617
   PubMed Web of Science ®Google Scholar
• KimWS, LeeSS, LeeCM, et al. Hepatitis C and not Hepatitis B virus is a risk factor for anti-tuberculosis drug induced liver injury. BMC Infect Dis. 2016;16:50. doi:10.1186/s12879-016-1344-226833347
   PubMed Web of Science ®Google Scholar
• ChangTE, HuangYS, ChangCH, PerngCL, HuangYH, HouMC. The susceptibility of anti-tuberculosis drug-induced liver injury and chronic hepatitis C infection: a systematic review and meta-analysis. J Chin Med Assoc. 2018;81(2):111–118. doi:10.1016/j.jcma.2017.10.00229198550
   PubMed Web of Science ®Google Scholar
• ChienJY, HuangRM, WangJY, et al. Hepatitis C virus infection increases hepatitis risk during anti-tuberculosis treatment. Int J Tuberc Lung Dis. 2010;14(5):616–621.20392356
   PubMed Web of Science ®Google Scholar
• ChenL, BaoD, GuL, et al. Co-infection with hepatitis B virus among tuberculosis patients is associated with poor outcomes during anti-tuberculosis treatment. BMC Infect Dis. 2018;18(1):295. doi:10.1186/s12879-018-3192-829970037
   PubMed Web of Science ®Google Scholar
• Tuberculosis Branch of Chinese Medical Association. Guidelines for the diagnosis and treatment of tuberculosis. Chin J Tubercul Respir Dis. 2001;24(2):70–74.
   Google Scholar
• Tuberculosis Branch of Chinese Medical Association. Guidelines for the diagnosis and treatment of antituberculous drug-induced liver injury. Chin J Tubercul Respir Dis. 2019;42(5):343–356.
   Google Scholar
• Fatty Liver and Alcoholic Liver Disease Group, Hepatology Society, Chinese Medical Association. Guidelines for the diagnosis and treatment of nonalcoholic fatty liver disease. Chin J Hepatol. 2006;14(3):161–163.
   Google Scholar
• Pharmaceutical Liver Disease Group, Liver Disease Branch, Chinese Medical Association. Guidelines for the diagnosis and treatment of drug-induced liver injury. Chin J Hepatol. 2015;23(11):810–820.
   Google Scholar
• WangNT, HuangYS, LinMH, HuangB, PerngCL, LinHC. Chronic hepatitis B infection and risk of antituberculosis drug-induced liver injury: systematic review and meta-analysis. J Chin Med Assoc. 2016;79(7):368–374. doi:10.1016/j.jcma.2015.12.00627032895
   PubMed Web of Science ®Google Scholar
• ZhengJ, GuoMH, PengHW, CaiXL, WuYL, PengXE. The role of hepatitis B infection in anti-tuberculosis drug-induced liver injury: a meta-analysis of cohort studies. Epidemiol Infect. 2020;148:e290. doi:10.1017/S095026882000286133222713
   PubMed Web of Science ®Google Scholar
• MakA, ChoT, UetrechtJ. Use of an animal model to test whether non-alcoholic fatty liver disease increases the risk of idiosyncratic drug-induced liver injury. J Immunotoxicol. 2018;15(1):90–95. doi:10.1080/1547691X.2018.146798229733743
   PubMed Web of Science ®Google Scholar
• Ortega-AlonsoA, StephensC, LucenaMI, AndradeRJ. Case characterization, clinical features and risk factors in drug-induced liver injury. Int J Mol Sci. 2016;17(5):714. doi:10.3390/ijms17050714
   PubMed Web of Science ®Google Scholar
• MassartJ, BegricheK, MoreauC, FromentyB. Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity. J Clin Transl Res. 2017;3(Suppl 1):212–232.28691103
   PubMedGoogle Scholar
• LammertC, ImlerT, TealE, ChalasaniN. Patients with chronic liver disease suggestive of nonalcoholic fatty liver disease may be at higher risk for drug-induced liver injury. Clin Gastroenterol Hepatol. 2019;17(13):2814–2815. doi:10.1016/j.cgh.2018.12.01330580093
   PubMed Web of Science ®Google Scholar
• CaoSP, YangL, GaoLC, FuMJ. Liver injury of 182 primary pulmonary tuberculosis patients induced by antituberculosis drugs. Cent South Pharm. 2015;13(9):1003–1006.
   Google Scholar
• WangF, YangYF. Analysis of risk factors of drug induced liver injury caused by antituberculosis treatment. Pract Pharm Clin Remedies. 2014;17(10):1326–1328.
   Google Scholar
• ChiX, QiY, ChenJ, CaiHF, LiWF, SongSB. Logistic regression analysis of clinical characteristics and risk factors of drug-induced liver injury induced by primary antituberculous therapy. Shaanxi Med J. 2019;48(1):67–70.
   Google Scholar
• ZhangT, DuJ, YinX, et al. Adverse events in treating smear-positive tuberculosis patients in China. Int J Environ Res Public Health. 2015;13(1):86. doi:10.3390/ijerph13010086
   Web of Science ®Google Scholar
• LiX, WangL, LiD, NiuJ, GaoP. Dyslipidemia is a risk factor for the incidence and severity of Drug-Induced Liver Injury (DILI): a retrospective population-based study in China. Med Sci Monit. 2019;25:3344–3353. doi:10.12659/MSM.91668731059494
   PubMed Web of Science ®Google Scholar
• ChenM, SuzukiA, BorlakJ, Andrade RaúlJ, IsabelLM. Drug-induced liver injury: interactions between drug properties and host factors. J Hepatol. 2015;63:503–514. doi:10.1016/j.jhep.2015.04.01625912521
   PubMed Web of Science ®Google Scholar
• FromentyB. Drug-induced liver injury in obesity. J Hepatol. 2013;58:824–826. doi:10.1016/j.jhep.2012.12.01823298629
   PubMed Web of Science ®Google Scholar
• BouazziOE, HammiS, BourkadiJE, et al. First line anti-tuberculosis induced hepatotoxicity: incidence and risk factors. Pan Afr Med J. 2016;25:167. doi:10.11604/pamj.2016.25.167.1006028292129
   PubMed Web of Science ®Google Scholar
• LatiefM, DarWR, SofiN, et al. Novel risk factors and early detection of anti tubercular treatment induced liver injury-looking beyond American Thoracic Society Guidelines. Indian J Tuberc. 2017;64(1):26–32. doi:10.1016/j.ijtb.2016.11.00228166913
   PubMedGoogle Scholar
• ZhaoH, WangY, ZhangT, WangQ, XieW. Drug-induced liver injury from anti-tuberculosis treatment: a retrospective cohort study. Med Sci Monit. 2020;26:e920350.32145061
   PubMed Web of Science ®Google Scholar
• AbbaraA, ChittyS, RoeJK, et al. Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK. BMC Infect Dis. 2017;17(1):231. doi:10.1186/s12879-017-2330-z28340562
   PubMed Web of Science ®Google Scholar